BRAF and neoplasm: In the model, we examined several factors, including age, gender, tumor stage, TIL status (overall and specific cell types), TMB, neoantigen level, TP53, BRAF, and IDH1 mutation state, copy number variation of PD-L1, PDCD1, and CTLA4, and immuno-activating/suppressive cytokines and cytolytic activity (Figure 5, Table 3).